主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
RVPH
#3760
Reviva Pharmaceuticals Holdings, Inc. Common Stock
0.2
1
-4.55%
版块:
基础:
利润货币:
日范围
年范围
日变化
-4.55%
每月变动
-32.26%
6个月变化
-55.32%
年变化
-85.00%
前一天收盘价
0.2
2
Open
0.2
1
Bid
Ask
Low
0.2
1
High
0.2
1
交易量
6
市场
股票
医疗保健
RVPH
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
9.23 M
15.13 M
20.45 M
27.92 M
46.74 M
—
Valuation ratios
Enterprise value
71.97 M
14.05 M
62.47 M
124.88 M
71.12 M
155.19 M
Price to earnings ratio
—
—
3.18
3.22
-2.01
-4.45
Price to sales ratio
—
—
-396.93
-528.26
83.6
781.99
Price to cash flow ratio
—
—
-4.08
-4.46
-1.79
-4.08
Price to book ratio
—
—
6.27
22.1
73.84
44.38
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.43
-0.27
1.28
1.66
-1.93
-2.11
Return on equity %
0.51
-0.3
1.97
6.87
-36.82
6.04
Return on invested capital %
31.98
-25.89
-3 000.72
-2 076.88
-1 214.46
-1 362.62
Gross margin %
—
—
100
100
100
400
Operating margin %
—
—
12.48 K
16.51 K
-4 291.66
5 705.23
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
-12.48 K
-16.43 K
-4 169.03
5 757.06
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
8.69
12.66
3.07
1.36
1.01
3.83
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
—
-0.01
-0.01
0.04
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0
—
—
—
—
—
Long term debt to total equity ratio
0
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
-0.97
-1.19
-1.01
-0.62
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
0.95
0.98
0.41
0.9
Net current asset value per share
—
—
0.95
0.98
0.44
0.97
Tangible book value per share
—
—
0.63
0.24
0.02
-0.01
Working capital per share
—
—
0.64
0.26
0
-0.08
Book value per share
—
—
0.63
0.24
0.02
-0.01
新闻
Vocal biomarker study supports brilaroxazine’s efficacy in schizophrenia
Chardan Capital 开始对 Reviva Pharmaceuticals 股票进行覆盖并给予买入评级
Chardan Capital assumes coverage on Reviva Pharmaceuticals stock with Buy rating
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—12/30/25 - TipRanks.com
H.C. Wainwright 重申 Reviva Pharmaceuticals 为"买入"评级
Reviva Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.16%
美国股市上涨;截至收盘道琼斯工业平均指数上涨0.16%
Reviva制药公司股价暴跌,因FDA要求进行第二次三期临床试验
Reviva Pharmaceuticals stock plunges after FDA requests second Phase 3 trial
FDA建议Reviva的精神分裂症药物进行第二次三期临床试验
FDA recommends second phase 3 trial for Reviva’s schizophrenia drug